Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are chronic type 2 inflammatory diseases that are frequently associated with each other. Dupilumab inhibits the dual signaling pathways of interleukin (IL)-4 and IL-13, which are key and central drivers of type 2 inflammation in CRSwNP. Omalizumab blocks the action of immunoglobulin E. Head-to-head studies are required to investigate the comparative efficacy and safety of these interventions. EVEREST (EValuating trEatment RESponses of dupilumab vs omalizumab in Type 2 patients) trial is designed to evaluate whether the efficacy of dupilumab is superior to omalizumab in treating patients with CRSwNP and comorbid asthma (ClinicalTrials.gov Identifiers: NCT04998604).
Objective
Here, we describe the EVEREST study design to compare the efficacy and safety of dupilumab compared to omalizumab over 24 weeks of treatment in patients with severe CRSwNP and comorbid asthma.
Methods
EVEREST is a global, phase 4 multicenter, randomized (1:1), double-blind, active-controlled trial. Approximately 422 adult patients with severe CRSwNP, symptoms of nasal congestion and loss of smell, and coexisting asthma will be recruited across 15 countries. The primary objective is to assess the efficacy of dupilumab compared to omalizumab in reducing the nasal polyp size and improving the sense of smell. The key secondary objectives are to evaluate the comparative efficacy in improving CRSwNP symptoms (eg, nasal congestion) and lung function. The safety will be evaluated in terms of treatment-emergent adverse events (AEs), serious AEs, and AEs of special interest.
Conclusions
EVEREST is the first head-to-head trial assessing the comparative efficacy and safety of 2 biologics in patients with severe CRSwNP and comorbid asthma. The study will provide evidence to help optimize treatment plans for patients that suffer from severe CRSwNP and comorbid asthma.
BachertCHanJKWagenmannM, et al.EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2021;147(1):29–36.
2.
ThomasMYawnBPriceD, et al.EPOS primary care guidelines: European position paper on the primary care diagnosis and management of rhinosinusitis and nasal polyps 2007—a summary. Prim Care Respir Med. 2008;17(2):79–89.
3.
ChenSZhouAEmmanuelB, et al.Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Cur Med Res Opin. 2020;36(11):1897–1911.
4.
BachertCPawankarRZhangL, et al.ICON: chronic rhinosinusitis. World Allergy Organ J. 2014;7(1):1–28.
5.
TomassenPVandeplasGVan ZeleT, et al.Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449–1456. e1444.
6.
MalinovschiAJansonCBorresM, et al.Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity. J Allergy Clin Immunol. 2016;138(5):1301–1308. e1302.
7.
RastogiSBosnic-AntievichSPavordI, et al.P198 Feno and blood eosinophils as biomarkers in predicting asthma exacerbations. Thorax. 2017;72:A190
8.
SchleichFNChevremontAPaulusV, et al.Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J. 2014;44(1):97–108.
9.
ZeigerRSSchatzMZhangF, et al.Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids. J Allergy Clin Immunol.2011;128(2):412–414.
10.
StaudacherAGPetersATKatoA, et al.Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis. Ann Allergy Asthma Immunol. 2020;124(4):318–325. DOI: 10.1016/j.anai.2020.01.013
11.
StevensWWPetersATTanBK, et al.Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7(8):2812–2820.e2813. DOI: 10.1016/j.jaip.2019.05.009
12.
BachertCBhattacharyyaNDesrosiersM, et al.Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy. 2021;14:127.
13.
FokkensWJLundVBachertC, et al.EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312–2319.
14.
PoetkerDMJakubowskiLALalD, et al.Oral corticosteroids in the management of adult chronic rhinosinusitis with and without nasal polyps: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2013;3(2):104–120. DOI: 10.1002/alr.21072
15.
PromsopaCKansaraSCitardiMJ, et al.Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol. 2016;6(4):373–377. DOI: 10.1002/alr.21674
16.
LaidlawTMMullolJWoessnerKM, et al.Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133–1141. DOI: 10.1016/j.jaip.2020.09.063
17.
KhanAVandeplasGThiMTH, et al.The global allergy and asthma European network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32–42.
18.
StevensWWPetersATHirschAG, et al.Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5(4):1061–1070. e1063.
19.
PhilpottCMErskineSHopkinsC, et al.Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK national chronic rhinosinusitis epidemiology study. Respir Res. 2018;19(1):1–9.
20.
WonH-KKimY-CKangM-G, et al.Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset. Ann Allergy Asthma Immunol. 2018;120(4):389–394.
21.
RollemaCvan RoonENde VriesTW. Inadequate quality of administration of intranasal corticosteroid sprays. J Asthma Allergy. 2019;12:91–94. DOI: 10.2147/jaa.S189523
22.
BorishLCohenNAChuppG, et al.Evaluating enrolment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps. Ann Allergy Asthma Immunol. 2022:1–9. DOI: 10.1016/j.anai.2022.04.004
23.
CampbellRG. Risks and management of long-term corticosteroid use in chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2018;26(1):1–7. DOI: 10.1097/moo.0000000000000421
24.
PriceDCastroMBourdinA, et al.Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety. Eur Respir Rev. 2020;29(155):190151. DOI: 10.1183/16000617.0151-2019
25.
MorseJCMillerCSeniorB. Management of chronic rhinosinusitis with nasal polyposis in the era of biologics. J Asthma Allergy. 2021;14:873.
26.
KaplanA. Canadian guidelines for chronic rhinosinusitis: clinical summary. Can Fam Physician. 2013;59(12):1275–1281.
27.
MullolJMariño-SánchezFVallsM, et al.The sense of smell in chronic rhinosinusitis. J Allergy Clin Immunol. 2020;145(3):773–776. DOI: 10.1016/j.jaci.2020.01.024
BachertCHanJKDesrosiersM, et al.Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650.
32.
LaidlawTMBachertCAminN, et al.Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Ann Allergy Asthma Immunol. 2021;126(5):584–592.e581. DOI: 10.1016/j.anai.2021.01.012
33.
MullolJLaidlawTMBachertC, et al.Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials. Allergy. 2022;77(4):1231–1244. DOI: 10.1111/all.15067
34.
GevaertPOmachiTACorrenJ, et al.Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605.
35.
BusseWCorrenJLanierBQ, et al.Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–190.
36.
SolerMMatzJTownleyR, et al.The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254–261.
37.
HanJKBachertCFokkensW, et al.Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141–1153. DOI: 10.1016/S2213-2600(21)00097-7
38.
OrtegaHGLiuMCPavordID, et al.Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
39.
RolandLTSmithTLSchlosserRJ, et al.Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from national institutes of health-sponsored workshop. Int Forum Allergy Rhinol. 2020;10(9):1037–1042. DOI: 10.1002/alr.22633
40.
DeCondeASMaceJCLevyJM, et al.Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550–555.
41.
HanJKBachertCLeeSE, et al.Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2021;132(2):265–271.
42.
ScaddingGHellingsPAlobidI, et al.Diagnostic tools in rhinology EAACI position paper. Clin Transl Allergy. 2011;1(1):1–39.
43.
DotyRLFryeREAgrawalU. Internal consistency reliability of the fractionated and whole University of Pennsylvania smell identification test. Percept Psycho. 1989;45(5):381–384.
44.
DotyRLShamanPDannM. Development of the University of Pennsylvania smell identification test: a standardized microencapsulated test of olfactory function. Physiol Behav. 1984;32(3):489–502.
45.
RanuHWildeMMaddenB. Pulmonary function tests. Ulster Med J. 2011;80(2):84.
46.
MillerMRHankinsonJBrusascoV, et al.Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
47.
BanerjiAPiccirilloJFThawleySE, et al.Chronic rhinosinusitis patients with polyps or polypoid mucosa have a greater burden of illness. Am J Rhinol. 2007;21(1):19–26.
48.
HopkinsCGillettSSlackR, et al.Psychometric validity of the 22-item sinonasal outcome test. Clin Otolaryngo. 2009;34(5):447–454.
49.
GraySTPhillipsKMHoehleLP, et al.The 22-item sino-nasal outcome test accurately reflects patient-reported control of chronic rhinosinusitis symptomatology. Int Forum Allergy Rhinol. 2017;7(10):945–951. DOI: 10.1002/alr.21992
50.
DoulaptsiMProkopakisESeysS, et al.Visual analogue scale for sino-nasal symptoms severity correlates with sino-nasal outcome test 22: paving the way for a simple outcome tool of CRS burden. Clin Transl Allergy. 2018;8(1):1–6.
51.
JuniperEO’byrnePGuyattG, et al.Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907.
52.
BarnesPCasaleTDahlR, et al.The asthma control questionnaire as a clinical trial endpoint: past experience and recommendations for future use. Allergy. 2014;69(9):1119–1140.
53.
GandhiNABennettBLGrahamNM, et al.Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. DOI: 10.1038/nrd4624
54.
NabaviMArshiSBahramiA, et al.Increased level of interleukin-13, but not interleukin-4 and interferon-gamma in chronic rhinosinusitis with nasal polyps. Allergol Immunopathol (Madr). 2014;42(5):465–471. DOI: 10.1016/j.aller.2013.06.007
55.
BachertCMannentLNaclerioRM, et al.Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–479.
56.
PetersATHanJKHellingsP, et al.Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2021;9(6):2461–2471. e2465.
57.
HellingsPVerhoevenEFokkensW. State-of-the-art overview on biological treatment for CRSwNP. Rhinology. 2021;59(2):151–163.
MullolJBachertCAminN, et al.Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2021;21:S2213–S2198.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
